Daratumumab market seen growing to $9 billion by 2030

The global market for daratumumab, sold as Darzalex, rose to an estimated $6.19 billion in 2026 and is projected to reach $9.02 billion by 2030, according to a new industry report. Growth is being driven by broader use in multiple myeloma, expanding combination therapies and rising demand for targeted cancer drugs.

Why it matters: - Daratumumab is a key treatment in multiple myeloma, so market growth signals continued demand for targeted cancer therapies. - The report points to expanding use in hematologic cancers and combination regimens as a major commercial and clinical shift. - North America leads the market, underscoring where oncology adoption and research investment are most concentrated.

What happened: - The Business Research Company released its Detailed Daratumumab and Darzalex Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the daratumumab or Darzalex market at $6,189.36 million in 2026, up from $5,618.3 million in 2025. - The report projects the market will reach $9,024.5 million by 2030. - The report says North America held the largest share of the market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offers a free sample of the report here. - The full report is available here.

The details: - Daratumumab, marketed as Darzalex, is a monoclonal antibody used mainly to treat multiple myeloma. - The drug binds to CD38, a protein expressed on multiple myeloma cells and some other malignant and normal immune cells. - By targeting CD38, daratumumab helps destroy abnormal plasma cells in the bone marrow. - The 2025-to-2026 market increase reflects a 10.2% CAGR. - The forecast through 2030 reflects a 9.9% CAGR. - The report ties past growth to regulatory approvals for multiple myeloma treatment, its CD38 targeting, limited options for relapsed disease, broader adoption by oncology centers and improved patient survival. - The report says future growth will come from broader use in combination therapies, rising multiple myeloma prevalence, higher oncology investment, new clinical indications and patient access programs. - The report highlights growing use in multiple myeloma, combination regimens with other cancer drugs, earlier placement in treatment lines, hospital-based monoclonal antibody therapies and expanding use in other hematologic cancers. - The report says increasing bone marrow cancer cases are supporting demand for daratumumab-based treatments. - The report links that rise to an aging global population, better detection, environmental factors, lifestyle habits and genetic predispositions. - In January 2025, the American Cancer Society said about 3,770 new primary bone and joint cancer cases and about 2,190 related deaths were expected in the US that year. - The report also cites rising adoption of biologics and targeted therapies as a growth driver. - In February 2024, the Personalized Medicine Coalition reported that the US FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - Daratumumab’s market growth reflects a broader oncology trend toward biologic drugs that target a specific molecular pathway rather than using traditional broad-acting treatments. - The emphasis on combination therapy and earlier-line use suggests daratumumab is moving from a specialty option to a more embedded part of treatment pathways. - North America’s lead likely reflects faster uptake of advanced cancer drugs and deeper research and treatment infrastructure.

What's next: - The report expects the market to keep expanding as multiple myeloma incidence rises and clinical use widens. - The company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, hotspot infographics and updated trend analysis. - More information is available from The Business Research Company’s contact channels and social accounts, including LinkedIn and other platforms.